The LATAM Fabry disease market is estimated to be valued at USD 105.41 Mn in 2026 and is expected to reach USD 165.92 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 6.9% during the forecast period. The main factors that will drive growth in the market include increased awareness about rare genetic diseases, developments in diagnostics, increased use of ERTs, and novel treatment techniques. The role played by governments in controlling rare diseases and improving the healthcare infrastructure in Latin America has also been contributing towards growth in the market.
Consistent growth in the market is due to developments in enzyme replacement therapy, chaperone therapy, genetic testing, and personalized treatment solutions. Growth in the market is also supported by increased investment in research on rare diseases, improved newborn screening programs, and cooperation between pharmaceutical companies and healthcare organizations. Costly treatment, late diagnoses, poor awareness about the diseases, and lack of access to new treatment techniques in some countries are the key barriers to growth in the market.
The parenteral segment is expected to capture the highest market share, accounting for about 68% of the market in 2026. The high market share of the parenteral segment is owing to the increased use of IV-based enzyme replacement therapies, which have been established as the primary mode of treatment for Fabry disease. The development of biological drugs and improved accessibility of patients to IV-based treatments are expected to drive the growth of the segment during the forecast period.
Brazil is anticipated to lead the LATAM Fabry disease market over the forecast period on account of the presence of a large number of patients, an efficient healthcare system, an increase in the availability of treatment facilities, and supportive government programs related to the treatment of rare diseases.
Company Profiles
1. Novartis
Company Overview
- Headquarters: Basel, Switzerland
- Establishment Year: 1996
- Employee Strength: Approximately 75,000+ employees
- Leadership: Mr. Vas Narasimhan, Chief Executive Officer
- Core Services/Products: Rare disease therapies, gene therapies, specialty pharmaceuticals, cardiovascular medicines, oncology treatments, and advanced biologics.
- Geographic Presence: Operations in more than 140 countries worldwide.
SWOT Analysis
- Strengths
- Impressive portfolio of innovative drugs for rare conditions
- High investments on R&D activities
- Weaknesses
- Depends heavily on patented specialty drugs
- Has premium prices for novel drugs
- Opportunities
- Gene therapy expansion for rare genetic conditions
- Rare disease drug availability in Latin America
- Threats
- Expiration of some of the key patents
- Pricing and reimbursement issues
2. Teva Pharmaceutical Industries Ltd.
Company Overview
- Headquarters: Tel Aviv, Israel
- Establishment Year: 1901
- Employee Strength: Approximately 37,000+ employees
- Leadership: Mr. Richard Francis, President and Chief Executive Officer
- Core Services/Products: Generic medicines, specialty pharmaceuticals, biologics, rare disease treatments, and central nervous system therapies.
- Geographic Presence: Presence in over 60 countries.
